A Study of Simmitinib Plus Irinotecan in Advanced Esophageal Squamous Cell Carcinoma
Status:
RECRUITING
Trial end date:
2026-01-30
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of simmitinib plus irinotecan liposome in the treatment of advanced esophageal squamous cell carcinoma, and to evaluate the PK of the drug and the correlation between biomarkers and clinical efficacy of simmitinib plus irinotecan liposome.